Table 1 Characteristics of included randomized controlled trials
From: Choices in fluid type and volume during resuscitation: impact on patient outcomes
Trial | N | Population | Type of fluid | Outcomes | Conclusion | |||
|---|---|---|---|---|---|---|---|---|
Intervention | N | Control | N | |||||
Myburgh 2012 (CHEST) | 6,651 | ICU patients | 6% HES (130/0.4) | 3,315 | Saline | 3,336 | 90-day mortality, AKI, RRT | No mortality difference; increased AKI and RRT use with HES |
Perner 2012 | 798 | ICU patients with severe sepsis | 6% HES (130.0.42) | 398 | Ringer’s acetate | 400 | 90-day mortality, RRT | Increased 90-day mortality with HES; increased use of RRT with HES |
Yates 2013 | 202 | Medium to high risk elective colorectal surgery patients | 6% HES (130/0.4) | 104 | Hartmann’s solution | 98 | Day 5 post-op GI morbidity; post-op complications, LOS, coagulation and inflammation | No difference in any of the measured outcomes |
Annane 2013 (CRISTAL) | 2,857 | ICU patients with hypovolemic shock | Colloids (gelatins, dextrans, HES, 4% or 20% albumin) | 1,414 | Crystalloids (isotonic or hypertonic saline, Ringer’s lactate) | 1,443 | 28- and 90-day mortality; days alive without the need for RRT, MV, or vasopressors | No difference in 28-day mortality; 90-day mortality lower in colloid group |
Caironi 2014 (ALBIOS) | 1,810 | ICU patients with severe sepsis or septic shock | 20% albumin and crystalloid | 903 | Crystalloid solution | 907 | 28- and 90-day mortality; organ dysfunction, LOS | No difference in mortality or other outcomes |